Plain-English translation of NCT05702463 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing aspirin—a common blood-thinning medication—in people with type 2 diabetes to find the best dose and form that actually works. Some people's bodies don't respond well to standard aspirin doses, and this study aims to figure out which dosing schedule helps the most people. Researchers will test three different ways of taking aspirin over several weeks and measure how well each one prevents blood clots.
People with type 2 diabetes are at higher risk for heart attacks and strokes, and aspirin is often used to help prevent these events. However, not everyone responds the same way to the same aspirin dose—some people's blood cells don't thin as expected. This study exists to find which aspirin regimen works best for the most people, so doctors can prescribe the right dose for their diabetic patients.
You likely qualify if…
You likely don't qualify if…
You'll start by taking a standard aspirin dose for 7 days, then return for blood tests to see how your body responds. If your body doesn't respond well to that dose, you'll be randomly assigned to try one of three different aspirin regimens for 7 days each, with blood tests between each regimen. The entire study involves several clinic visits over a few weeks where researchers will draw blood and measure how well the medication is working for you.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Canada